Shifting Paradigm in the Incidence of Postmenopausal Breast Cancer in Sulaimani in 10 Years Period
DOI:
https://doi.org/10.24086/cuesj.v10n1y2026.pp40-48Keywords:
Postmenopausal breast cancer, Incidence trend, Joinpoint regression, Molecular subtypes, Sulaimani, IraqAbstract
Breast cancer (BC) remains the most common malignancy among women worldwide, with postmenopausal women accounting for a substantial proportion of cases; however, data on long-term incidence trends and molecular subtype patterns in Iraqi Kurdistan remain limited. This study evaluated 10-year incidence trends of postmenopausal BC in Sulaimani, Iraq, and characterized associated demographic factors and molecular subtype distributions. A cross-sectional study was conducted using clinical records from Hiwa Cancer Hospital and Zhianawa Hospital between 2015 and 2024. Age-standardized incidence rates (ASIRs) were calculated, and temporal trends were assessed using Joinpoint regression analysis to estimate annual percent change (APC). Demographic, clinical, and molecular characteristics, including estrogen receptor, progesterone receptor, Human epidermal growth factor receptor 2 (HER2), and Ki-67 based immunohistochemical subtypes (Luminal A, Luminal B, HER2-enriched, and Triple Negative), were analyzed in a representative sample of postmenopausal BC patients. The ASIR of BC increased from 119.1/100,000 in 2015 to 164.0/100,000 in 2024, reflecting a 37.8% overall rise. Joinpoint regression identified a marked increase between 2015 and 2017 (APC = +10.24%), followed by a plateau from 2017 to 2024 (APC = +0.02%). Women aged 55–64 years constituted the largest proportion of postmenopausal cases, with evidence of a shift toward younger postmenopausal age groups over time. Obesity was highly prevalent among patients. Luminal B was the predominant molecular subtype, while HER2-enrichedand triple-negative subtypes declined significantly across the study period. In conclusion, postmenopausal BC incidence in Sulaimani has increased over the past decade, with recent stabilization and a shift toward hormone receptor-positive molecular subtypes. These findings underscore the importance of strengthening early detection strategies, addressing modifiable risk factors, and optimizing subtype-guided management to improve BC outcomes in the region.
Downloads
References
1. M. R. Brogna, G. Ferrara, V. Varone, A. Montone, M. Schiano, M. DelSesto and F. Collina. Evaluation and comparison of prognostic multigene tests in early-stage breast cancer: Which is the most effective? A literature review exploring clinical utility to enhance therapeutic management in luminal patients. Molecular Carcinogenesis, vol. 64, no. 5, pp. 789-800, 2025. DOI: https://doi.org/10.1002/mc.23893
2. D. A. N. Albuquerque, M. T. Vianna, L. A. F. Sampaio, E. H. C. N. Vasiliu and E. H. C. Neves Filho. Systematic review and meta-analysis of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry. NPJ Digital Medicine, vol. 8, p. 144, 2025. DOI: https://doi.org/10.1038/s41746-025-01483-8
3. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209-249, 2021. DOI: https://doi.org/10.3322/caac.21660
4. R. Karthiga, K. Narasimhan, V. Thanikaiselvan, M. Hemalatha R and Amirtharajan. Review of AI & XAI-based breast cancer diagnosis methods using various imaging modalities. Multimedia Tools and Applications, vol. 84, pp. 2209-2260, 2025. DOI: https://doi.org/10.1007/s11042-024-20271-2
5. E. Heer, A. Harper, N. Escandor, V. McCormack and M. M. Fidler-Benaoudia. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. The Lancet Global Health, vol. 8, pp. e1027-e1037, 2020. DOI: https://doi.org/10.1016/S2214-109X(20)30215-1
6. H. C. Yildirim, C. Kapar, B. Koksal, M. Seyyar, P. C. Sanci, M. Guliyev, P. Perkin, M. Buyukkor, S. Yaslikaya, N. Majidova, M. Keskinkilic, D. Ozaskin, T. Avci, T. K. Gunes, M. Arcagok. & S. Aksoy. Efficacy of first-line CDK4/6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: A Turkish oncology group (TOG) study. Journal of Chemotherapy, vol. 37, no. 1, pp. 69-75, 2025. DOI: https://doi.org/10.1080/1120009X.2024.2330835
7. J. Huang, P. S. Chan, V. Lok, X. Chen, H. Ding, Y. Jin, J. Yuan, X. Q. Lao, Z. J. Zheng and M. C. Wong. Global incidence and mortality of breast cancer: A trend analysis. Aging (Albany NY), vol. 13, no. 4, pp. 5748-5803, 2021. DOI: https://doi.org/10.18632/aging.202502
8. H. Jie W. Ma and C. Huang. Diagnosis, prognosis, and treatment of triple-negative breast cancer: A review. Breast Cancer (Dove Med Press), vol. 17, pp. 265-274, 2025. DOI: https://doi.org/10.2147/BCTT.S516542
9. A. M. Taha, H. A. Kamel, Y. Khlidj, D. S. Salem, S. A. A. Saed, K. Abouelmagd, D. Nguyen, E. Shash, S. Chapagain and L. Kassem. Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis. Medicine (Baltimore), vol. 104, no. 8, p. e41632, 2025. DOI: https://doi.org/10.1097/MD.0000000000041632
10. M. M. Al-Hashimi. Trends in breast cancer incidence in Iraq during the period 2000-2019. Asian Pacific Journal of Cancer Prevention, vol. 22, no. 12, pp. 3889-3896, 2021. DOI: https://doi.org/10.31557/APJCP.2021.22.12.3889
11. K. E. Lukong. Understanding breast cancer - the long and winding road. BBA Clinical, vol. 7, pp. 64-77, 2017. DOI: https://doi.org/10.1016/j.bbacli.2017.01.001
12. S. Duan and I. L. Buxton. Evolution of medical approaches and prominent therapies in breast cancer. Cancer (Basel), vol. 14, p. 2450, 2022. DOI: https://doi.org/10.3390/cancers14102450
13. B. Fisher. From Halsted to prevention and beyond: Advances in the management of breast cancer during the twentieth century. European Journal of Cancer, vol. 35, no. 14, pp. 1963-1973, 1999. DOI: https://doi.org/10.1016/S0959-8049(99)00217-8
14. H. J. Burstein. Fifty years of systemic therapy for breast cancer: From one size fits all to tailored therapy. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology, Annual Meeting, vol. 34, no. 1, pp. 1-3, 2014. DOI: https://doi.org/10.14694/EdBook_AM.2014.34.e1
15. M. Arnold, E. Morgan, H. Rumgay, A. Mafra, D. Singh, M. Laversanne, J. Vignat, J. R. Gralow, F. Cardoso, S. S. Siesling and I. Soerjomataram. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, vol. 66, pp. 15-23, 2022. DOI: https://doi.org/10.1016/j.breast.2022.08.010
16. R. Sharma. Global, regional, national burden of breast cancer in 185 countries: Evidence from GLOBOCAN 2018. Breast Cancer Research and Treatment, vol. 187, no. 2, pp. 557-567, 2021. DOI: https://doi.org/10.1007/s10549-020-06083-6
17. S. Azadnajafabad, S. S. Moghaddam, E. Mohammadi, N. Rezaei, M. M. Rashidi, N. Rezaei, A. H. Mokdad, M. Naghavi, C. J. L. Murray, B. Larijani, F. Farzadfar and GBD 2019 NAME Breast Cancer Collaborators. Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990-2019: A systematic analysis for the global burden of disease study. Frontiers in Oncology, vol. 13, p. 1132816, 2019. DOI: https://doi.org/10.3389/fonc.2023.1132816
18. M. A. Chawsheen, R. H. Al-Naqshbandi and F. A. K. Ishaac. Epidemiological trends and molecular characterization of breast carcinoma in Erbil, Kurdistan Region of Iraq. ARO-the Scientific Journal of Koya University, vol. 13, no. 1, pp. 86-93, 2025. DOI: https://doi.org/10.14500/aro.11860
19. S. Safiri, M. Noori, S. A. Nejadghaderi, M. J. M. Sullman, N. L. Bragazzi, A. Almasi-Hashiani, M. A. Mansournia and A. A. Kolahi. Burden of female breast cancer in the Middle East and North Africa region, 1990-2019. Archives of Public Health, vol. 80, no. 1, p. 168, 2022. DOI: https://doi.org/10.1186/s13690-022-00918-y
20. M. Al-Hashimi and E. M. N. Mahmood. Spatial statistical analysis of female breast cancer incidence in Iraq during 2000-2015. Malaysian Journal of Public Health Medicine, vol. 21, no. 2, pp. 75-87, 2021. DOI: https://doi.org/10.37268/mjphm/vol.21/no.2/art.750
21. A. Zannetti. Breast cancer: From pathophysiology to novel therapeutic approaches 2.0. International Journal of Molecular Sciences, vol. 24, p. 2542, 2023. DOI: https://doi.org/10.3390/ijms24032542
22. X. Xiong, L. W. Zheng, Y. Ding, Y. F. Chen, Y. W. Cai, L. P. Wang,L. Huang, C. C. Liu, Z. M. Shao and K. D. Yu. Breast cancer: Pathogenesis and treatments. Signal Transduction and Targeted Therapy, vol. 10, p. 49, 2025. DOI: https://doi.org/10.1038/s41392-024-02108-4
23. S. K. Chabuk, A. K. Hameed, S. A. A. Naser and A. Al-Fahham. The epidemiology and pathophysiology of breast cancer. International Journal of Health and Medical Research, vol. 3, no. 9, pp. 661-665, 2024.
24. R. S. Lee and J. M. Fawwal. Emerging role of epigenetic modifiers in breast cancer pathogenesis and therapeutic response. Cancers (Basel), vol. 15, p. 4005, 2023. DOI: https://doi.org/10.3390/cancers15154005
25. M. M. Babu, K. G. Madhavi, K. S. Kumar, and G. Prakash. A comprehensive insight into breast cancer: Risks, pathophysiology, awareness, and prevention. Breast Cancer, vol. 39, no. 12, pp. 25-28, 2025.
26. E. I. Obeagu and G. U. Obeagu. Breast cancer: A review of risk factors and diagnosis. Medicine (Baltimore), vol. 103, p. e36905, 2024. DOI: https://doi.org/10.1097/MD.0000000000036905
27. M. S. Kareem and D. H. Taher. Anxiety and depression levels with risk factors of breast cancer patients in Erbil City-Iraq. Erbil Journal of Nursing and Midwifery, vol. 4, no. 2, pp. 76-85, 2021. DOI: https://doi.org/10.15218/ejnm.2021.09
28. D. A. Saeed and A. Sheikha. Identifying risk factors for the development of breast cancer among women attending Hiwa Hematology/Oncology Hospital in the Sulaimaniyah, Iraqi Kurdistan. Journal of Zankoy Sulaimani Part A, vol. 25, no. 1, pp. 23-32, 2023. DOI: https://doi.org/10.17656/jzs.10891
29. K. M-Amen, O. Abdullah, A. Amin, Z. Mohamed, L. Sulaiman, M. Shekha, H. Najmuldeen, B. Barzingi, A. Salih, D. Mahmood, H. Othman, F. Rahman, D. Mohammad, F. Salih and S. K. Ali. Cancer Statistics in Kurdistan Region of Iraq: A Tale of Two Cities [Preprint]; 2021. DOI: https://doi.org/10.21203/rs.3.rs-142129/v1
30. K. M-Amen, O. S. Abdullah, A. M. S. Amin, Z. A. Mohamed, B. Hasan, M. Shekha, H. H. Najmuldeen, F. M. Rahman, Z. Housein, A. M. Salih, A. S. Mohammed, L. R. Sulaiman, B. T. Barzingi, D. Mahmood, H. E. Othman, D. K. Mohammad, F. M. Salih, S. A. K. Ali, T. S. Mohamad, K. Mahmood, G. O. Othman, M. H. Aali, G. Qader, B. M. Hussen, F. A. Awla, S. W. Kareem, F. A. Qadir, D. M. Taher, A and Salihi A. Cancer incidence in the Kurdistan region of Iraq: Results of a seven-year cancer registration in Erbil and Duhok governorates. Asian Pacific Journal of Cancer Prevention, vol. 23, no. 2, pp. 601-615, 2022. DOI: https://doi.org/10.31557/APJCP.2022.23.2.601
31. R. A. Majid, H. A. Mohammed, H. M. Saeed, B. M. Safar, R. M. Rashid and M. D. Hughson. Breast cancer in Kurdish women of Northern Iraq: Incidence, clinical stage, and case-control analysis of parity and family risk. BMC Womens Health, vol. 9, no. 1, p. 33, 2009. DOI: https://doi.org/10.1186/1472-6874-9-33
32. J. Gnerlich, A. D. Deshpande, D. B. Jeffe, A. Sweet, N. White and J. A. Margenthaler. Elevated breast cancer mortality in young women (<40 years) compared with older women is attributed to poorer survival in early-stage disease. Journal of the American College of Surgeons, vol. 207, no. 3, pp. 341-347, 2008. DOI: https://doi.org/10.1016/j.jamcollsurg.2008.12.001
33. N. Patel, S. Shah and S. Chacha. A prospective comparative study of breast cancer in pre- and postmenopausal women. National Journal of Physiology Pharmacy and Pharmacology, vol. 15, no. 2, pp. 204-204, 2025. DOI: https://doi.org/10.5455/NJPPP.2025.v15.i2.15
34. A. M. Ameen. The clinicopathological and molecular landscape of breast cancer patients: A retrospective study in Sulaimaniyah, Iraq. Scientific Reports, vol. 15, p. 30549, 2025. DOI: https://doi.org/10.1038/s41598-025-12896-6
35. M. M. Al-Hashimi and X. J. Wang. Breast cancer in Iraq: Incidence trends from 2000 to 2009. Asian Pacific Journal of Cancer Prevention, vol. 15, no. 1, pp. 281-286, 2014. DOI: https://doi.org/10.7314/APJCP.2014.15.1.281
36. Iraqi Cancer Registry. Results of the Iraqi Cancer Registry 2015- 2019. Baghdad, Iraq: Iraqi Ministry of Health, 2020.
37. R. T. Othman, R. Abdulljabar and A. Saeed, S. S. Kittani, H. M. Sulaiman, S. A. Mohammed, R. M. Rashid and N. R. Hussein. Breast cancer characteristics in Kurdistan Region of Iraq: A single-center experience. Asian Pacific Journal of Cancer Prevention, vol. 12, pp. 1261-1264, 2011.
38. T. J. Key, P. N. Appleby, G. K. Reeves, A. Roddam, J. F. Dorgan, C. Longcope, F. Z. Stanczyk, H. E. Stephenson Jr., R. T. Falk, R. Miller, A. Schatzkin, D. S. Allen, I. S. Fentiman, T. J. Key… & S. R. Miller. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute, vol. 95, no. 16, pp. 1218-1226, 2003. DOI: https://doi.org/10.1093/jnci/djg022
39. H. A. M. Ameen. ALLRED score directly associated to body mass index in Kurdish premenopausal women with breast cancer. Journal of Sulaimani Medical College, vol. 8, no. 3, pp. 181-187, 2018. DOI: https://doi.org/10.17656/jsmc.10167
40. O. S. Habib and A. A. Al-Janabi. Obesity and breast cancer risk among Iraqi women. Saudi Medical Journal, vol. 31, no. 10, pp. 1129-1134, 2010.
41. R. Ghiasvand, E. S. Maram, S. Tahmasebi and S. H. Tabatabaee. Risk factors for breast cancer among young Iranian women in Southern Iran. Asian Pacific Journal of Cancer Prevention, vol. 12, no. 4, pp. 1243-1246, 2011.
42. G. O. Abdulrahman Jr. and G. A. Rahman. Epidemiology of breast cancer in Middle Eastern women. International Journal of Women’s Health, vol. 4, pp. 103- 13, 2012. DOI: https://doi.org/10.1155/2012/915610
43. F. A. Vostakolaei, M. J. M. Broeders, N. Rostami, J. Van Dijck, T. Feuth, L. Kiemeney, A. L. Verbeek. Molecular subtypes and survival of breast cancer in Iran. Breast, vol. 22, no. 4, pp. 548-551, 2013.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Niga A. Rasul; Kamal A. Saeed (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
